Discounted Cash Flow
Abbott Laboratories
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $20.9b | $1.4b | $2.1b | 6.7% | $0.94 |
| 2017 | $27.4b (31.3%) | $477.0m (-65.9%) | $4.4b (113.0%) | 1.7% (-74.1%) | $0.27 (-71.3%) |
| 2018 | $30.6b (11.6%) | $2.4b (396.4%) | $4.9b (10.6%) | 7.7% (344.7%) | $1.34 (396.3%) |
| 2019 | $31.9b (4.3%) | $3.7b (55.7%) | $4.5b (-8.3%) | 11.6% (49.2%) | $2.07 (54.5%) |
| 2020 | $34.6b (8.5%) | $4.5b (21.9%) | $5.7b (27.3%) | 13.0% (12.4%) | $2.52 (21.7%) |
| 2021 | $43.1b (24.5%) | $7.1b (57.3%) | $8.6b (51.1%) | 16.4% (26.4%) | $3.97 (57.5%) |
| 2022 | $43.7b (1.3%) | $6.9b (-2.0%) | $9.4b (8.6%) | 15.9% (-3.2%) | $3.94 (-0.8%) |
| 2023 | $40.1b (-8.1%) | $5.7b (-17.5%) | $7.1b (-24.4%) | 14.3% (-10.2%) | $3.28 (-16.8%) |
| 2024 | $42.0b (4.6%) | $13.4b (134.2%) | $8.4b (18.1%) | 31.9% (123.9%) | $7.67 (133.8%) |
| 2025 | $44.3b (5.7%) | $6.5b (-51.3%) | $9.4b (12.0%) | 14.7% (-53.9%) | $3.73 (-51.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.